Integral Health Asset Management, LLC reported 87 positions worth $2.42B for the quarter ended Jun 30, 2026, up 29.0% on the prior quarter. It opened 27 new positions, added to 22, trimmed 21 and exited 24. Its largest holding is Revolution Medicines, Inc. at 11.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CVS CVS HEALTH Corp | +950.0K | +633.3% | $98.28M | 4.7% |
| AXSM Axsome Therapeutics, Inc. | +265.0K | +757.1% | $64.86M | 3.03% |
| EW Edwards Lifesciences Corp | +455.0K | +267.6% | $41.16M | 2.34% |
| ABT Abbott Laboratories | +400.0K | – | $36.30M | 1.5% |
| UNH Unitedhealth Group Inc | +85.0K | – | $35.33M | 1.46% |
| THC Tenet Healthcare Corp | +165.0K | – | $30.87M | 1.28% |
| DGX Quest Diagnostics Inc | +140.0K | +233.3% | $29.67M | 1.75% |
| SYRE Spyre Therapeutics, Inc. | +325.0K | – | $28.85M | 1.19% |
| NVO Novo Nordisk A S | +600.0K | – | $28.76M | 1.19% |
| TVTX Travere Therapeutics, Inc. | +375.0K | – | $21.30M | 0.88% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| AZN Astrazeneca Plc | -250.0K | -100.0% | $49.31M | Exited |
| BTSG BrightSpring Health Services, Inc. | -700.0K | -56.0% | $48.82M | 1.59% |
| REGN Regeneron Pharmaceuticals, Inc. | -45.0K | -52.9% | $28.06M | 1.03% |
| CNC Centene Corp | -350.0K | -53.8% | $22.47M | 0.796% |
| ASND Ascendis Pharma A/S | -70.0K | -60.9% | $18.67M | 0.496% |
| FMS Fresenius Medical Care AG | -775.0K | -100.0% | $17.48M | Exited |
| ISRG Intuitive Surgical Inc | -35.0K | -100.0% | $16.13M | Exited |
| TARS Tarsus Pharmaceuticals, Inc. | -200.0K | -100.0% | $14.03M | Exited |
| GILD Gilead Sciences, Inc. | -100.0K | -100.0% | $13.94M | Exited |
| LFST LifeStance Health Group, Inc. | -1.30M | -30.2% | $13.92M | 1.33% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ABT Abbott Laboratories | +400.0K | $36.30M | 1.5% |
| UNH Unitedhealth Group Inc | +85.0K | $35.33M | 1.46% |
| THC Tenet Healthcare Corp | +165.0K | $30.87M | 1.28% |
| SYRE Spyre Therapeutics, Inc. | +325.0K | $28.85M | 1.19% |
| NVO Novo Nordisk A S | +600.0K | $28.76M | 1.19% |
| TVTX Travere Therapeutics, Inc. | +375.0K | $21.30M | 0.88% |
| MDT Medtronic plc | +200.0K | $15.65M | 0.647% |
| WAT Waters Corp | +40.0K | $15.00M | 0.62% |
| IRTC iRhythm Holdings, Inc. | +90.0K | $10.71M | 0.442% |
| IART Integra Lifesciences Holdings Corp | +550.0K | $9.88M | 0.408% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| AZN Astrazeneca Plc | -250.0K | $49.31M | 2.63% |
| FMS Fresenius Medical Care AG | -775.0K | $17.48M | 0.932% |
| ISRG Intuitive Surgical Inc | -35.0K | $16.13M | 0.86% |
| TARS Tarsus Pharmaceuticals, Inc. | -200.0K | $14.03M | 0.748% |
| GILD Gilead Sciences, Inc. | -100.0K | $13.94M | 0.743% |
| ELAN Elanco Animal Health Inc | -550.0K | $13.16M | 0.702% |
| DNTH Dianthus Therapeutics, Inc. | -150.0K | $12.59M | 0.671% |
| DXCM Dexcom Inc | -175.0K | $10.99M | 0.586% |
| IRON Disc Medicine, Inc. | -170.0K | $10.87M | 0.58% |
| NRIX Nurix Therapeutics, Inc. | -700.0K | $10.85M | 0.579% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVMD Revolution Medicines, Inc. | Healthcare | 1.50M | $280.92M | 11.61% | 0 | 0.0% | Unchanged | 0.7% |
| 2 | INSM INSMED Inc | Healthcare | 1.60M | $170.59M | 7.05% | +100.0K | +6.7% | Added | 0.73% |
| 3 | CYTK Cytokinetics Inc | Healthcare | 1.60M | $136.30M | 5.63% | 0 | 0.0% | Unchanged | 1.15% |
| 4 | CVS CVS HEALTH Corp | Healthcare | 1.10M | $113.80M | 4.7% | +950.0K | +633.3% | Added | 0.09% |
| 5 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 2.00M | $81.26M | 3.36% | +400.0K | +25.0% | Added | 1.86% |
| 6 | VERA Vera Therapeutics, Inc. | Healthcare | 1.75M | $75.09M | 3.1% | +150.0K | +9.4% | Added | 2.44% |
| 7 | AXSM Axsome Therapeutics, Inc. | Healthcare | 300.0K | $73.43M | 3.03% | +265.0K | +757.1% | Added | 0.57% |
| 8 | CAH Cardinal Health Inc | Healthcare | 300.0K | $71.27M | 2.95% | +30.0K | +11.1% | Added | 0.13% |
| 9 | ROIV Roivant Sciences Ltd. | Healthcare | 2.00M | $70.78M | 2.93% | 0 | 0.0% | Unchanged | 0.28% |
| 10 | RYTM Rhythm Pharmaceuticals, Inc. | Healthcare | 550.0K | $61.07M | 2.52% | -50.0K | -8.3% | Reduced | 0.8% |
| 11 | EW Edwards Lifesciences Corp | Healthcare | 625.0K | $56.54M | 2.34% | +455.0K | +267.6% | Added | 0.11% |
| 12 | ALHC Alignment Healthcare, Inc. | Healthcare | 2.00M | $47.62M | 1.97% | -575.0K | -22.3% | Reduced | 0.96% |
| 13 | MRK Merck & Co., Inc. | Healthcare | 350.0K | $44.98M | 1.86% | -75.0K | -17.6% | Reduced | 0.01% |
| 14 | DGX Quest Diagnostics Inc | Healthcare | 200.0K | $42.39M | 1.75% | +140.0K | +233.3% | Added | 0.18% |
| 15 | QURE uniQure N.V. | Healthcare | 900.0K | $41.45M | 1.71% | 0 | 0.0% | Unchanged | 1.3% |
Tip. Select a row to see that position’s full history at Integral Health Asset Management.
As of its Q2 2026 13F filing, Integral Health Asset Management, LLC’s five largest positions were Revolution Medicines, Inc. (RVMD) at 11.6%, INSMED Inc (INSM) at 7.1%, Cytokinetics Inc (CYTK) at 5.6%, CVS HEALTH Corp (CVS) at 4.7%, Edgewise Therapeutics, Inc. (EWTX) at 3.4% of the reported portfolio.
Integral Health Asset Management, LLC reported a 13F portfolio worth $2.42B across 87 positions for Q2 2026. That is up 29.0% from the previous quarter.
Its largest purchases by value were CVS HEALTH Corp ($98.28M), Axsome Therapeutics, Inc. ($64.86M), Edwards Lifesciences Corp ($41.16M). It opened 27 new positions.
Its largest sales by value were Astrazeneca Plc ($49.31M), BrightSpring Health Services, Inc. ($48.82M), Regeneron Pharmaceuticals, Inc. ($28.06M). It exited 24 positions entirely.
From the Form 13F-HR reports Integral Health Asset Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.